

Caroline Dive

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3222247/publications.pdf>

Version: 2024-02-01

94
papers

13,960
citations

61984

43
h-index

38395

95
g-index

97
all docs

97
docs citations

97
times ranked

20139
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	27.0	1,786
2	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	27.8	1,287
3	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
4	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1556-1563.	1.6	788
5	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 525-532.	1.6	755
6	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019, 19, 289-297.	28.4	692
7	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. <i>Nature Medicine</i> , 2014, 20, 897-903.	30.7	608
8	Progress and prospects of early detection in lung cancer. <i>Open Biology</i> , 2017, 7, 170070.	3.6	552
9	Molecular analysis of circulating tumour cellsâ€“biology and biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 129-144.	27.6	535
10	Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3163-3169.	7.0	470
11	Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis. <i>Journal of Cell Biology</i> , 1999, 144, 903-914.	5.2	413
12	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. <i>Journal of Thoracic Oncology</i> , 2012, 7, 306-315.	1.1	411
13	Early detection of cancer. <i>Science</i> , 2022, 375, eaay9040.	12.6	291
14	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. <i>Nature Medicine</i> , 2017, 23, 114-119.	30.7	260
15	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 926-937.	7.0	256
16	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	3.8	223
17	Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. <i>Cancer Cell</i> , 2020, 37, 485-495.	16.8	223
18	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299.	9.4	208

#	ARTICLE	IF	CITATIONS
19	Vasculogenic mimicry in small cell lung cancer. <i>Nature Communications</i> , 2016, 7, 13322.	12.8	206
20	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. <i>Nature Medicine</i> , 2019, 25, 738-743.	30.7	202
21	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
22	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. <i>Nature Medicine</i> , 2019, 25, 1534-1539.	30.7	146
23	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5153-5164.	7.0	126
24	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1582-1590.	0.7	122
25	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	1.1	119
26	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. <i>Nature Cancer</i> , 2020, 1, 437-451.	13.2	103
27	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. <i>Analyst</i> , 2016, 141, 669-678.	3.5	95
28	Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. <i>Oncogene</i> , 2001, 20, 7668-7676.	5.9	84
29	Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1793-1797.	1.1	80
30	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. <i>Molecular Oncology</i> , 2016, 10, 566-574.	4.6	74
31	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. <i>Cell Reports</i> , 2016, 16, 644-656.	6.4	73
32	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the "U" out of "CUP". <i>British Journal of Cancer</i> , 2019, 120, 141-153.	6.4	71
33	Circulating tumor cells and CDX models as a tool for preclinical drug development. <i>Translational Lung Cancer Research</i> , 2017, 6, 397-408.	2.8	68
34	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4549-4558.	7.0	63
35	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. <i>Lancet Oncology</i> , 2018, 19, e470-e481.	10.7	63
36	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. <i>Molecular Cell</i> , 2020, 80, 562-577.	9.7	54

#	ARTICLE	IF	CITATIONS
37	MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and dna damage. <i>International Journal of Cancer</i> , 1995, 61, 502-508.	5.1	51
38	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	6.4	51
39	Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models. <i>Molecular Cancer Research</i> , 2017, 15, 1012-1016.	3.4	49
40	PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF- κ B pathways. <i>Scientific Reports</i> , 2017, 7, 15441.	3.3	49
41	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 216-230.	1.1	49
42	An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity. <i>Toxicological Sciences</i> , 2014, 140, 3-15.	3.1	47
43	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , 2018, 9, 4672.	12.8	47
44	Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. <i>Journal of Clinical Investigation</i> , 2011, 121, 1075-1087.	8.2	46
45	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1836-1843.	1.1	45
46	Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 343-349.	2.8	44
47	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5860-5872.	7.0	44
48	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 115-122.e2.	2.3	43
49	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992.	5.1	41
50	Targeting DNA damage in SCLC. <i>Lung Cancer</i> , 2017, 114, 12-22.	2.0	36
51	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11610.	3.3	36
52	<i>in vivo</i> culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. <i>British Journal of Pharmacology</i> , 2019, 176, 436-450.	5.4	34
53	Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights. <i>Frontiers in Oncology</i> , 2021, 11, 672195.	2.8	34
54	Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. <i>Oncogene</i> , 2000, 19, 5487-5497.	5.9	31

#	ARTICLE	IF	CITATIONS
55	Small cell lung cancer enters the era of precision medicine. <i>Cancer Cell</i> , 2021, 39, 297-299.	16.8	31
56	Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. <i>BJU International</i> , 2014, 114, E70-E73.	2.5	30
57	Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1248-1260.	4.1	30
58	Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. <i>Translational Lung Cancer Research</i> , 2013, 2, 382-97.	2.8	29
59	Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. <i>FEBS Letters</i> , 2005, 579, 5123-5128.	2.8	28
60	The clinical utility of circulating tumour cells in patients with small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 409-417.	2.8	28
61	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. <i>Open Biology</i> , 2021, 11, 200247.	3.6	28
62	The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2373-2383.	4.1	27
63	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 1-11.	5.4	27
64	twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis. <i>Bioinformatics</i> , 2017, 33, 2743-2745.	4.1	26
65	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. <i>EBioMedicine</i> , 2015, 2, 841-850.	6.1	24
66	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016, 115, 228-235.	6.4	23
67	Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs. <i>Molecular Cancer Research</i> , 2009, 7, 955-965.	3.4	22
68	BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737. <i>Neoplasia</i> , 2014, 16, 147-W16.	5.3	22
69	Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response. <i>Npj Genomic Medicine</i> , 2016, 1, 16020.	3.8	22
70	Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients. <i>Journal of Proteome Research</i> , 2019, 18, 3369-3382.	3.7	22
71	Method validation of circulating tumour cell enumeration at low cell counts. <i>BMC Cancer</i> , 2013, 13, 415.	2.6	20
72	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1999-2019.	7.0	20

#	ARTICLE	IF	CITATIONS
73	A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs. <i>Nature Communications</i> , 2022, 13, 2690.	12.8	19
74	Somatically mutated <i>ABL</i> 1 is an actionable and essential NSCLC survival gene. <i>EMBO Molecular Medicine</i> , 2016, 8, 105-116.	6.9	18
75	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. <i>Molecular Oncology</i> , 2016, 10, 282-291.	4.6	18
76	Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform. <i>Journal of Thoracic Oncology</i> , 2015, 10, 784-792.	1.1	16
77	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	2.6	16
78	Pazopanib and Fostretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	1.4	14
79	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6652.	12.8	14
80	Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. <i>BMC Cancer</i> , 2014, 14, 226.	2.6	13
81	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 785-797.	1.8	13
82	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. <i>Cell Reports</i> , 2021, 37, 109979.	6.4	13
83	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016, 173, 274-282.	2.5	12
84	Molecular analysis of single circulating tumour cells following long-term storage of clinical samples. <i>Molecular Oncology</i> , 2017, 11, 1687-1697.	4.6	12
85	Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid. <i>Cell Death and Differentiation</i> , 1997, 4, 787-795.	11.2	11
86	Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. <i>BMC Cancer</i> , 2015, 15, 387.	2.6	9
87	Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. <i>Npj Genomic Medicine</i> , 2018, 3, 15.	3.8	9
88	Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. <i>EJNMMI Research</i> , 2019, 9, 18.	2.5	9
89	Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants. <i>Lung Cancer</i> , 2020, 150, 216-220.	2.0	7
90	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7

#	ARTICLE	IF	CITATIONS
91	<i>In silico</i> error correction improves cfDNA mutation calling. <i>Bioinformatics</i> , 2019, 35, 2380-2385.	4.1	6
92	Dynamics of circulating vascular endothelial growth factor predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1781-1789.	2.4	3
93	OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S263.	1.1	2
94	Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. , 0, .		1